Methamphetamine self-administration is associated with persistent biochemical alterations in striatal and cortical dopaminergic terminals in the rat

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Krasnova, Irina N ^a   Justinova, Zuzana ^a,b   Ladenheim, Bruce ^a   Jayanthi, Subramaniam ^a   McCoy, Michael T ^a   Barnes, Chanel ^a   Warner, John E ^a   Goldberg, Steven R ^a   Cadet, Jean Lud ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; NORADRENALIN; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABUSE; DRUG DOSE ESCALATION; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; RAT; ANIMAL; DRUG EFFECT; METABOLISM;

ANIMALIA; MAMMALIA; RATTUS;

ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; RATS; SELF ADMINISTRATION; SEROTONIN; TYROSINE 3-MONOOXYGENASE;

EID: 77649311333     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008790     Document Type: Article

References (68)

1. Degenhardt L, Roxburgh A, Black E, Bruno R, Campbell G, et al. (2008) The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev 27: 243-252.
2. Griffiths P, Mravcik V, Lopez D, Klempova D (2008) Quite a lot of smoke but very limited fire-the use of methamphetamine in Europe. Drug Alcohol Rev 27: 236-242.
3. Maxwell JC, Rutkowski BA (2008) The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992-2007. Drug Alcohol Rev 27: 229-235.
4. McKetin R, Kozel N, Douglas J, Ali R, Vicknasingam B, et al. (2008) The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 27: 220-228.
5. Darke S, Kaye S, McKetin R, Duflou J (2008) Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27: 253-262.
6. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, et al. (2008) Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134: 301-310.
7. Cherner M, Suarez P, Casey C, Deiss R, Letendre S, et al. (2009) Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults. Drug Alcohol Depend.
8. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, et al. (2006) Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185: 327-338.
9. Sim T, Simon SL, Domier CP, Richardson K, Rawson RA, et al. (2002) Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis 21: 75-89.
10. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, et al. (2000) Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9: 222-231.
11. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
12. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, et al. (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17: 275-297.
13. Chang L, Alicata D, Ernst T, Volkow N (2007) Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 Suppl 1: 16-32.
14. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54: 1344-1349.
15. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, et al. (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28: 5756-5761.
16. Kitamura O, Tokunaga I, Gotohda T, Kubo S (2007) Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Legal Med 121: 163-168.
17. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, et al. (2004) Why is parkinsonism not a feature of human methamphetamine users? Brain 127: 363-370.
18. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, et al. (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703.
19. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, et al. (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63: 90-100.
20. Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, et al. (2009) Brain serotonin transporter in human methamphetamine users. Psychopharmacology (Berl) 202: 649-661.
21. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202.
22. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
23. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
24. Hadlock GC, Baucum AJ, King JL, Horner KA, Cook GA, et al. (2009) Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J Pharmacol Exp Ther 329: 169-174.
25. Krasnova IN, Hodges AB, Ladenheim B, Rhoades R, Phillip CG, et al. (2009) Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice. Neurosci Res 65: 160-165.
26. Ladenheim B, Krasnova IN, Deng X, Oyler JM, Polettini A, et al. (2000) Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6. Mol Pharmacol 58: 1247-1256.
27. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105: 605-616.
28. Xu W, Zhu JP, Angulo JA (2005) Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 58: 110-121.
29. Cho AK, Melega WP (2002) Patterns of methamphetamine abuse and their consequences. J Addict Dis 21: 21-34.
30. Kramer JC, Fischman VS, Littlefield DC (1967) Amphetamine abuse. Pattern and effects of high doses taken intravenously. Jama 201: 305-309.
31. Cadet JL, Krasnova IN, Ladenheim B, Cai NS, McCoy MT, et al. (2009) Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain. Neurotox Res 15: 252-259.
32. Cadet JL, McCoy MT, Cai NS, Krasnova IN, Ladenheim B, et al. (2009) Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum. PLoS One 4: e7812.
33. Graham DL, Noailles PA, Cadet JL (2008) Differential neurochemical consequences of an escalating dose-binge regimen followed by single-day multiple-dose methamphetamine challenges. J Neurochem 105: 1873-1885.
34. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2003) Escalating dose methamphetamine pretreatment alters the behavioral and neurochemical profiles associated with exposure to a high-dose methamphetamine binge. Neuropsychopharmacology 28: 1730-1740.
35. Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK (2005) Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization. Psychopharmacology (Berl) 180: 501-512.
36. Kitamura O, Wee S, Specio SE, Koob GF, Pulvirenti L (2006) Escalation of methamphetamine self-administration in rats: a dose-effect function. Psychopharmacology (Berl) 186: 48-53.
37. Mandyam CD, Wee S, Eisch AJ, Richardson HN, Koob GF (2007) Methamphetamine self-administration and voluntary exercise have opposing effects on medial prefrontal cortex gliogenesis. J Neurosci 27: 11442-11450.
38. Wee S, Wang Z, Woolverton WL, Pulvirenti L, Koob GF (2007) Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32: 2238-2247.
39. Mandyam CD, Wee S, Crawford EF, Eisch AJ, Richardson HN, et al. (2008) Varied access to intravenous methamphetamine self-administration differentially alters adult hippocampal neurogenesis. Biol Psychiatry 64: 958-965.
40. Stefanski R, Lee SH, Yasar S, Cadet JL, Goldberg SR (2002) Lack of persistent changes in the dopaminergic system of rats withdrawn from methamphetamine self-administration. Eur J Pharmacol 439: 59-68.
41. Shepard JD, Chuang DT, Shaham Y, Morales M (2006) Effect of methamphetamine self-administration on tyrosine hydroxylase and dopamine transporter levels in mesolimbic and nigrostriatal dopamine pathways of the rat. Psychopharmacology (Berl) 185: 505-513.
42. Schwendt M, Rocha A, See RE, Pacchioni AM, McGinty JF, et al. (2009) Extended methamphetamine self-administration in rats results in a selective reduction of dopamine transporter levels in the prefrontal cortex and dorsal striatum not accompanied by marked monoaminergic depletion. J Pharmacol Exp Ther 331: 555-562.
43. Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 32: 638-647.
44. Davidson C, Lee TH, Ellinwood EH (2005) Acute and chronic continuous methamphetamine have different long-term behavioral and neurochemical consequences. Neurochem Int 46: 189-203.
45. Friedman SD, Castaneda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61: 35-44.
46. Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2003) The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482: 151-154.
47. Stephans S, Yamamoto B (1996) Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 72: 593-600.
48. Deng X, Ladenheim B, Tsao LI, Cadet JL (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J Neurosci 19: 10107-10115.
49. Fumagalli F, Gainetdinov RR, Valenzano KJ, Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18: 4861-4869.
50. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS (1989) Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486: 73-78.
51. Zhu JP, Xu W, Angulo JA (2005) Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res 1049: 171-181.
52. Cadet JL, Brannock C (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32: 117-131.
53. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658.
54. Reynolds A, Laurie C, Mosley RL, Gendelman HE (2007) Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 82: 297-325.
55. Dong Y, Benveniste EN (2001) Immune function of astrocytes. Glia 36: 180-190.
56. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006) Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088: 219-229.
57. Wilms H, Zecca L, Rosenstiel P, Sievers J, Deuschl G, et al. (2007) Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 13: 1925-1928.
58. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23: 474-483.
59. Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ, et al. (2005) Special lecture: glial reactivity after damage: implications for scar formation and neuronal recovery. Clin Neurosurg 52: 29-44.
60. Stoll G, Jander S, Schroeter M (2002) Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system. Adv Exp Med Biol 513: 87-113.
61. Albertson TE, Derlet RW, Van Hoozen BE (1999) Methamphetamine and the expanding complications of amphetamines. West J Med 170: 214-219.
62. Neale A, Abraham S, Russell J (2009) ''Ice'' use and eating disorders: a report of three cases. Int J Eat Disord 42: 188-191.
63. Bray GA (1993) Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 119: 707-713.
64. Ricca V, Castellini G, Mannucci E, Monami M, Ravaldi C, et al. (2009) Amphetamine derivatives and obesity. Appetite 52: 405-409.
65. Bittner SE, Wagner GC, Aigner TG, Seiden LS (1981) Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats. Pharmacol Biochem Behav 14: 481-486.
66. Bardsley ME, Bachelard HS (1981) Catecholamine levels and tyrosine hydroxylase activities in rat brain regions after chronic treatment with, and withdrawal of, methamphetamine. Biochem Pharmacol 30: 1543-1549.
67. Krasnova IN, Betts ES, Dada A, Jefferson A, Ladenheim B, et al. (2007) Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox Res 11: 107-130.
68. Krasnova IN, Ladenheim B, Cadet JL (2005) Amphetamine induces apoptosis of medium spiny striatal projection neurons via the mitochondria-dependent pathway. Faseb J 19: 851-853.